Vincent Chung, M.D.

(877) 460-4673
Vincent Chung, M.D.
Medical Oncologist
Clinical Expertise
  • Pancreatic Cancer
  • Gastrointestinal Cancers
  • Phase 1/Early Therapeutics
Research Area
  • Gastrointestinal Cancer
Academic Appointments
  • Professor, Department of Medical Oncology & Therapeutics Research
Clinical Teams
Bile Duct Cancer
Colorectal Cancer
Esophageal Cancer
Gallbladder Cancer
Gastrointestinal Cancers
Gastrointestinal Carcinoid Tumors
Hereditary Colorectal Cancer Multidisciplinary Program
Liver Cancers and Liver Tumors
Medical Oncology & Therapeutics Research
Pancreatic Cancer
Small Intestine Cancer
Stomach (Gastric) Cancer
Research Teams
Developmental Cancer Therapeutics Program (CCC)

Vincent Chung, M.D., is a medical oncologist specializing in pancreatic cancer and gastrointestinal cancers. A member of the City of Hope® team since 2002, Dr. Chung, was voted one of “America's Top Doctors” by Castle Connolly in 2013.

Dr. Chung leads a long list of clinical trials examining new drugs to treat advanced solids tumors and immunotherapy options for inoperable pancreatic cancer.

Dr. Chung received his medical degree from the University of Tennessee at Memphis, and was chief resident at California Pacific Medical Center in San Francisco.

Location

Education & Experience

Board Certifications

  • 2005, Diplomate, American Board of Oncology
  • 2001, Diplomate, American Board of Internal Medicine

Degrees

  • 1994–1998, M.D., Medicine, University of Tennessee at Memphis, Memphis, TN
  • 1990–1993, B.A., Molecular and Cell Biology/Biochemistry, University of California Berkeley, Berkeley, CA

Fellowship

  • 2002–2005, City of Hope, Duarte, CA

Residency

  • 2001–2002, Chief Resident, Medicine, California Pacific Medical Center, San Francisco, CA
  • 1999–2001, Resident, Medicine, California Pacific Medical Center, San Francisco, CA

Internship

  • 1998–1999, Intern, Medicine, California Pacific Medical Center, San Francisco, CA

Professional Experience

  • 2020–present, Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
  • 2005–2020, Associate Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
  • 2004–2005, Fellow, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
  • 2002–2004, Fellow, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA

Awards & Memberships

Memberships

  • 2005–present, American Association of Cancer Research
  • 2004–present, American Society of Clinical Oncology
  • 2004–present, American Society of Hematology
  • 1999–2003, American College of Physicians, American Society of Internal Medicine

Publications

  • Wainberg ZA, Weekes CD, Furqan M, Kasi PM, Devoe CE, Leal AD, Chung V, Perry JR, Kheoh T, McNeil LK, Welkowsky E, DeMuth PC, Haqq CM, Pant S, O'Reilly EM; Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results. Nat Med. 2025 Aug 11. doi: 10.1038/s41591-025-03876-4. PMID: 40790272
  • Ferrell BR, Borneman T, Zachariah F, Sun V, Co N, Chung V; Feasibility Testing of an APRN-Led Model of Care for Transition of Patients After Completion of Phase I Trials.J Adv Pract Oncol. 2025 May 3:1-12. doi: 10.6004/jadpro.2025.16.7.12. Online ahead of print. PMID: 40599199
  • Smith SJ, Meng F, Lingeman RG, Li CM, Li M, Boneh G, Seppälä TT, Phan T, Li H, Burkhart RA, Parekh V, Rahmanuddin S, Melstrom LG, Hickey RJ, Chung V, Liu Y, Malkas LH, Raoof M. Therapeutic Targeting of Oncogene-induced Transcription-Replication Conflicts in Pancreatic Ductal Adenocarcinoma. Gastroenterology. 2025 Mar 21:S0016-5085(25)00533-5. doi: 10.1053/j.gastro.2025.02.038. PMID: 40209809
  • Klempner SJ, Sonbol MB, Wainberg ZA, Uronis HE, Chiu VK, Scott AJ, Iqbal S, Tejani MA, Chung V, Stilian MC, Thoma M, Zhang Y, Kagey MH, Baum J, Sirard CA, Altura RA, Ajani JA. DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish. J Clin Oncol. 2025 Jan 20;43(3):339-349. doi: 10.1200/JCO.24.00410. Epub 2024 Oct 21. PMID: 39432867
  • Chung V, Alistar A, Becerra C, Kasi A, Borazanci E, Jameson GS, Roe DJ, Wertheim BC, Cridebring D, Truitt M, Downes M, Barrett MT, Korn R, Lee K, Han H, Evans R, Von Hoff DD. Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction. Oncologist. 2025 Jan 17;30(1):oyae323. doi: 10.1093/oncolo/oyae323. PMID: 39846984 Clinical Trial.
  • Cloyd JM, Sarna A, Arango MJ, Bates SE, Bhutani MS, Bloomston M, Chung V, Dotan E, Ferrone CR, Gambino PF, Goenka AH, Goodman KA, Hall WA, He J, Hogg ME, Jayaraman S, Kambadakone A, Katz MHG, Khorana AA, Ko AH, Koay EJ, Kooby DA, Krishna SG, Larsson LK, Lee RT, Maitra A, Massarweh NN, Mikhail S, Muzaffar M, O'Reilly EM, Palta M, Petzel MQB, Philip PA, Reyngold M, Santa Mina D, Sohal DPS, Sundaresan TK, Tsai S, Turner KL, Vreeland TJ, Walston S, Washington MK, Williams TM, Wo JY, Snyder RA. Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2024 Dec 4:e245191. doi: 10.1001/jamasurg.2024.5191. PMID: 39630427
  • Borazanci EH, Bahary N, Chung V, Huyck TK, Kio EA, Chiorean EG, Skeel RT, Alese OB, Cardin DB, Fountzilas C, Hanna WT, Leal AD, Lee V, Noonan AM, Philip PA, Wainberg ZA, Pashova H, Mann G, Oberstein PE. Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study. Oncologist. 2024 Nov 4;29(11):957-965. doi: 10.1093/oncolo/oyae210. PMID: 39191530
  • Li D, Crook C, Chung V, Brar G, Fakih M, Barzi A, Melstrom L, Singh G, Fong Y, Frankel P, Raoof M. Safety of pressurized intraperitoneal aerosolized chemotherapy in biliary cancer patients with peritoneal metastases. Future Oncol. 2024 Sep 12:1-11. doi: 10.1080/14796694.2024.2394013. PMID: 39263892
  • Soto-Perez-de-Celis E, Dale W, Katheria V, Kim H, Fakih M, Chung V, Lim D, Mortimer J, Cabrera Chien L, Charles K, Roberts E, Vazquez J, Moreno J, Lee T, Fernandes Dos Santos Hughes S, Sedrak MS, Sun CL, Li D. Outcome prioritization and preferences among older adults with cancer starting chemotherapy in a randomized clinical trial. Cancer. 2024 Apr 17. doi: 10.1002/cncr.35333.PMID: 38630903.
  • Dias E Silva D, Chung V; Neoadjuvant treatment for pancreatic cancer: Controversies and advances, Cancer Treat Res Commun. 2024 Mar 11:39:100804. doi: 10.1016/j.ctarc.2024.100804. PMID: 38508132 DOI: 10.1016/j.ctarc.2024.100804

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
5.0
Provider listen carefully to you
5.0
Show respect for what you say
4.9
Provider explain in way you understand
4.9
Know important info medical history
4.9
Spend enough time with you
4.9
Rate provider 0-10
4.8
Recommend this provider office
03/16/26
Super recommended - Verified patient
03/16/26
Super attentive all the staff - Verified patient
02/25/26
Dr Chung was very kind and informative. - Verified patient
02/16/26
Excellent - Verified patient
02/16/26
Excellent care - Verified patient